Detalhe da pesquisa
1.
Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
Hematol Oncol
; 36(4): 633-637, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29956350
2.
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Blood Adv
; 7(7): 1130-1136, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36053786
3.
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Blood Adv
; 7(23): 7361-7368, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37756532
4.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Lancet Haematol
; 8(12): e879-e890, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826411
5.
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.
Leuk Res
; 28(2): 139-47, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14654078
6.
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.
Leuk Lymphoma
; 45(1): 85-92, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15061202
7.
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.
Leuk Lymphoma
; 45(2): 315-20, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15101717
8.
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Clin Cancer Res
; 17(9): 2977-86, 2011 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21402714
9.
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Cancer
; 116(18): 4283-90, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20564149
10.
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
Cancer
; 98(5): 978-82, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12942565